Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan
Language English Country United States Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
23426788
DOI
10.1093/ajh/hpt019
PII: hpt019
Knihovny.cz E-resources
- Keywords
- blood pressure, hypertension, metabolic effects, telmisartan, tissue-specific Pparg knockout mice.,
- MeSH
- Benzimidazoles pharmacokinetics MeSH
- Benzoates pharmacokinetics MeSH
- Angiotensin II Type 1 Receptor Blockers pharmacokinetics MeSH
- Hypertension drug therapy metabolism MeSH
- Insulin Resistance MeSH
- Blood Glucose metabolism MeSH
- Disease Models, Animal MeSH
- Mice, Knockout MeSH
- Mice MeSH
- PPAR gamma biosynthesis MeSH
- Telmisartan MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Benzimidazoles MeSH
- Benzoates MeSH
- Angiotensin II Type 1 Receptor Blockers MeSH
- Blood Glucose MeSH
- PPAR gamma MeSH
- Telmisartan MeSH
BACKGROUND: The angiotensin receptor blocker telmisartan has unique chemical properties that enable it to partially activate the peroxisome proliferator activated receptor gamma (PPARG) as well as block angiotensin II type 1 receptors. METHODS: To directly test whether some of the metabolic effects of telmisartan require the presence of PPARG, we studied mice in which the gene (Pparg) for PPARG had been deleted in fat or in muscle. RESULTS: We found that knockout of Pparg in fat tissue greatly impaired the ability of telmisartan to increase adiponectin levels and to enhance sensitivity to insulin-stimulated glucose incorporation into adipose tissue lipids. In contrast, muscle-specific Pparg knockout had relatively little or no impact on the ability of telmisartan to increase adiponectin levels or affect glucose metabolism either in fat or muscle. These findings provide compelling evidence that the ability of telmisartan to increase adiponectin levels and stimulate glucose use in adipose tissue may depend on the presence of PPARG in fat. CONCLUSIONS: We conclude that PPARG in adipose tissue is required for at least several of the metabolic actions of telmisartan.
References provided by Crossref.org